These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20721824)

  • 1. The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders.
    Grosset D; Grosset A
    IDrugs; 2010 Aug; 13(8):539-42. PubMed ID: 20721824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lingual protrusion dystonia: Manifestation during "on" periods in Parkinson's disease.
    Maiola R; Ramirez Gómez CC; Micheli F
    J Neurol Sci; 2016 Nov; 370():256-257. PubMed ID: 27772770
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinson's disease and related disorders--XVIII WFN World Congress.
    Grosset D
    IDrugs; 2010 Feb; 13(2):82-4. PubMed ID: 20127558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease.
    Santamato A; Ranieri M; Panza F; Zoccolella S; Frisardi V; Solfrizzi V; Amoruso MT; Amoruso L; Fiore P
    J Neurol; 2010 Jan; 257(1):139-41. PubMed ID: 19763384
    [No Abstract]   [Full Text] [Related]  

  • 5. An update on the use of botulinum toxin therapy in Parkinson's disease.
    Mills R; Bahroo L; Pagan F
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):511. PubMed ID: 25407133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of Parkinson's disease and extrapyramidal syndromes with classical drugs (what can be expected from them in the levodopa era and which should be used)].
    Sigwald J
    Therapeutique; 1972 Nov; 48(9):561-8. PubMed ID: 4650525
    [No Abstract]   [Full Text] [Related]  

  • 7. Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio.
    Espay AJ; Vaughan JE; Shukla R; Gartner M; Sahay A; Revilla FJ; Duker AP
    Mov Disord; 2011 Apr; 26(5):913-4. PubMed ID: 21432906
    [No Abstract]   [Full Text] [Related]  

  • 8. [New and future treatments for neurological disorders--knowledge essential to daily clinics and future prospects. Topics: 4. Parkinson's disease: progress in the medical treatment].
    Izawa M; Ito H
    Nihon Naika Gakkai Zasshi; 2013 Aug; 102(8):1938-45. PubMed ID: 24167851
    [No Abstract]   [Full Text] [Related]  

  • 9. Society for Neuroscience--38th Annual Meeting--Therapeutics for Parkinson's disease.
    Gotham S
    IDrugs; 2009 Jan; 12(1):10-1. PubMed ID: 19127496
    [No Abstract]   [Full Text] [Related]  

  • 10. Tardive syndrome and Parkinson's disease responsive to concomitant tetrabenazine and levodopa therapy.
    Kurtis MM; Franch O
    Parkinsonism Relat Disord; 2011 Dec; 17(10):774-6. PubMed ID: 21733737
    [No Abstract]   [Full Text] [Related]  

  • 11. Medical management of motor fluctuations.
    Dewey RB
    Neurol Clin; 2008 Aug; 26(3 Suppl):S15-27, v. PubMed ID: 18774440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gabapentin and motor fluctuations in Parkinson's disease.
    Chaná P; de Marinis A; Barrientos N
    Mov Disord; 1997 Jul; 12(4):608. PubMed ID: 9251083
    [No Abstract]   [Full Text] [Related]  

  • 13. Parkinson's disease: an enigma: highlights from the 8th International Congress of Parkinson's Disease and Movement Disorders, June 13-17, 2004, Rome, Italy.
    Weiner WJ
    Rev Neurol Dis; 2005; 2(1):20-2. PubMed ID: 16400299
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of early Parkinson's disease.
    Pahwa R; Lyons KE
    Curr Opin Neurol; 2014 Aug; 27(4):442-9. PubMed ID: 24950010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?
    Santamato A; Panza F; Solfrizzi V; Frisardi V; Ranieri M; Fiore P
    J Rehabil Med; 2008 Nov; 40(10):882-3. PubMed ID: 19242630
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A.
    Chen JJ; Swope DM
    J Clin Psychiatry; 2005 Feb; 66(2):267-8. PubMed ID: 15705018
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental Intrastriatal Applications of Botulinum Neurotoxin-A: A Review.
    Hawlitschka A; Wree A
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29735936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramipexole-associated fixed limb dystonia in Parkinson's disease.
    Pandey S; Jain S
    Parkinsonism Relat Disord; 2016 Oct; 31():159-160. PubMed ID: 27591073
    [No Abstract]   [Full Text] [Related]  

  • 20. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
    Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M
    Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.